Footnotes

Chapter 1 - Introduction

[1]        Journals of the Senate, 12 February 2015, p. 2156.

[2]        Journals of the Senate, 26 March 2015, p. 2461.

[3]        See: Journals of the Senate, 12 May 2015, p. 2555; Journals of the Senate, 15 June 2015, p. 2644; Journals of the Senate, 18 June 2015, p. 2707; Journals of the Senate, 25 June 2015, p. 2841.

[4]        Journals of the Senate, 27 November 2014, p. 1897.

Chapter 2 - Background issues

[1]        Victorian Law Reform Commission, Medicinal Cannabis: Issues Paper, 17 March 2015, p. 7.

[2]        Victorian Law Reform Commission, Medicinal Cannabis: Issues Paper, 17 March 2015, pp 6‑8.

[3]        University of Sydney academics joint submission, Submission 52, p. 4; Emeritus Professor David Penington AC, Submission 9, p. 1.

[4]        Submission 52, p. 3.

[5]        Submission 9, pp 1-2.

[6]        Submission 52, pp 4-5.

[7]        Submission 17, p. 3.

[8]        Submission 17, p. 3.

[9]        Committee Hansard, 31 March 2015, p. 47.

[10]      Submission 4, p. 12.

[11]      Submission 4, p. 13.

[12]      Submission 29, p. 1.

[13]      Submission 56, [p. 5].

[14]      Committee Hansard, 31 March 2015, p. 7.

[15]      See, for example: Emeritus Professor Laurence Mather, Submission 17, p. 6; National Drug and Alcohol Research Centre, Submission 19, pp 5-6.

[16]      Committee Hansard, 31 March 2015, p. 4.

[17]      Submission 19, p. 6.

[18]      Submission 19, p. 6.

[19]      Submission 19, p. 6 (internal citations omitted).

[20]      See National Drug and Alcohol Research Centre, Submission 19, pp 6-7.

[21]      Submission 17, p. 4.

[22]      Submission 9, pp 3 and 4.

[23]      Submission 51, p. 1.

[24]      Cancer Council Australia & Clinical Oncology Society of Australia, Submission 37, p. 5; Australian Medical Association, Submission 44, p. 1; Professor Wayne Hall, Submission 4, pp 5-6.

[25]      Committee Hansard, 31 March 2015, p. 7.

[26]      Committee Hansard, 31 March 2015, p. 42.

[27]      Committee Hansard, 31 March 2015, p. 14.

[28]      Submission 45, p. 2.

[29]      Submission 19, p. 3.

[30]      Department of Health, Submission 67, p. 2.

[31]      Submission 67, p. 2.

[32]      Department of Health, Submission 67, p. 3.

[33]      Any plant of the Cannabis genus is listed as a 'controlled plant' under Division 3.2 of the Criminal Code Regulations 2002.

[34]      Submission 67, p. 4.

[35]      Dr Lisa Studdert, TGA and Mr Nathan Smyth, Department of Health, Committee Hansard, 30 March 2015, pp 38-39.

[36]      Mr Nathan Smyth, Department of Health, Committee Hansard, 30 March 2015, p. 39.

[37]      Submission 67, p. 3.

[38]      Therapeutic Goods Act 1989, section 4.

[39]      Department of Health, Submission 67, p. 2.

[40]      Department of Health, Submission 67, p. 2.

[41]      Poisons Standard 2015, Introduction ii.

[42]      Poisons Standard 2015, Schedule 9.

[43]      Poisons Standard 2015, Classification iii.

[44]      Hemp seed oil is also exempted from Schedule 9 if it contains 50 mg/kg or less of tetrahydrocannabinols and is labelled with a warning statement 'Not for internal use' or 'Not to be taken'.

[45]      Committee Hansard, 30 March 2015, pp 36-37.

[46]      Schedule 8 Controlled Drugs are substances that are assessed as suitable to be made available for use but require restriction of manufacture, supply, distribution, possession and use to reduce abuse, misuse and physical or psychological dependence.

[47]      Department of Health, 'Medicinal Cannabis', 17 December 2014, http://www.health.gov.au/internet/main/publishing.nsf/Content/MC14-007515-medicinal-cannabis (accessed 22 May 2015).

[48]      Submission 23, p. 6.

[49]      Committee Hansard, 31 March 2015, pp 2-3.

[50]      Submission 4, pp 3-4.

[51]      Source: National Cannabis Prevention and Information Centre, 'Cannabis and the law', https://ncpic.org.au/professionals/publications/factsheets/cannabis-and-the-law/ (accessed 25 May 2015).

[52]      COAG Health Council, 'COAG Health Council Communique', 10 October 2014, http://www.coaghealthcouncil.gov.au/Publications/Communiques/ArtMID/522/ArticleID/10/10-October-2014-COAG-Health-Council-Communique (accessed 10 August 2015).

[53]      New South Wales Government, 'NSW leads the way on medical cannabis', 16 September 2014, http://www.nsw.gov.au/news/medical-cannabis-trial (accessed 25 May 2014).

[54]      New South Wales Government, 'Terminal Illness Cannabis Scheme', http://www.nsw.gov.au/tics (accessed 25 May 2015).

[55]      New South Wales Government, 'Terminal Illness Cannabis Scheme: Frequently Asked Questions', http://www.nsw.gov.au/tics-frequently-asked-questions (accessed 25 May 2015).

[56]      Committee Hansard, 31 March 2015, p. 39.

[57]      New South Wales Government, 'NSW leads the way on medical cannabis', 16 September 2014, http://www.nsw.gov.au/news/medical-cannabis-trial (accessed 25 May 2014).

[58]      New South Wales Government, 'Clinical Trials of Cannabis Products', http://www.health.nsw.gov.au/cannabis/Pages/clinical-trials.aspx (accessed 25 May 2015).

[59]      ABC News Online, 'Medicinal marijuana: NSW to run trials for epileptic children, terminally ill adults and cancer patients', 21 December 2014, http://www.abc.net.au/news/2014-12-21/medicinal-marijuana-nsw-govt-to-run-trial-for-epileptic-children/5981648 (accessed  5 May 2015).

[60]      New South Waled Government, 'Clinical Trials: Medical Use of Cannabis Fact Sheet', available at http://www.health.nsw.gov.au/cannabis/Pages/clinical-trials.aspx (accessed 25 May 2015).

[61]      New South Waled Government, 'Clinical Trials: Medical Use of Cannabis Fact Sheet', available at http://www.health.nsw.gov.au/cannabis/Pages/clinical-trials.aspx (accessed 25 May 2015).

[62]      ABC News Online, 'Medical cannabis: Queensland, Victoria and New South Wales join forces on cannabis oil in medical trials', http://www.abc.net.au/news/2015-04-19/queensland-victoria-join-nsw-medicinal-cannabis-trial/6403760 (accessed 25 May 2015).

[63]      ABC News Online, 'Victorian Government moves ahead with plans to legalist medical marijuana', 19 December 2014, http://www.abc.net.au/news/2014-12-19/victorian-government-moves-ahead-with-plans-to-legalise-medical/5980636 (accessed 25 May 2015).

[64]      Victorian Law Reform Commission, 'Terms of Reference – Medicinal cannabis', 23 December 2015, http://www.lawreform.vic.gov.au/projects/medicinal-cannabis/terms-reference-medicinal-cannabis (accessed 25 May 2015).

[65]      Victorian Law Reform Commission, Medicinal Cannabis Issues Paper, March 2015, p. 3.

[66]      Victorian Law Reform Commission, Medicinal Cannabis Issues Paper, March 2015, p. 166.

[67]      Victorian Law Reform Commission, 'Medicinal Cannabis – Issues Paper', 17 March 2015, http://www.lawreform.vic.gov.au/projects/medicinal-cannabis/medicinal-cannabis-issues-paper (accessed 25 May 2015).

[68]      Victorian Law Reform Commission, Medicinal Cannabis: Issues Paper, 17 March 2015, pp 108–109.

[69]      Victorian Law Reform Commission, Medicinal Cannabis: Issues Paper, 17 March 2015, ch. 6.

[70]      National Drug and Alcohol Research Centre of the University of New South Wales, Submission 19, p. 9.

[71]      National Drug and Alcohol Research Centre of the University of New South Wales, Submission 19, pp 9–11.

[72]      National Conference of State Legislatures, State Medical Marijuana Laws, http://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx (accessed 2 June 2015).

[73]      California Department of Public Health, ' What are Proposition 215 (Prop 215), the Compassionate Use Act of 1996, and Senate Bill (SB) 420', Medical Marijuana Program Frequently Asked Questions, https://www.cdph.ca.gov/programs/MMP/Pages/MMPFAQ.aspx#1 (accessed 2 June 2015).

[74]      California Department of Public Health, ' How much marijuana can I have in my possession?', Medical Marijuana Program Frequently Asked Questions, https://www.cdph.ca.gov/programs/MMP/Pages/MMPFAQ.aspx#31 (accessed 2 June 2015).

[75]      California Department of Public Health, ' How do I know if I qualify for a MMIC?', Medical Marijuana Program Frequently Asked Questions,  https://www.cdph.ca.gov/programs/MMP/Pages/MMPFAQ.aspx#4 (accessed 2 June 2015).

[76]      California Department of Public Health, 'I am a qualified patient. How and what documentation do I need to apply for a MMIC?', Medical Marijuana Program Frequently Asked Questions, https://www.cdph.ca.gov/programs/MMP/Pages/MMPFAQ.aspx#6 (accessed 2 June 2015).

[77]      California Department of Public Health, 'What is a primary caregiver?', Medical Marijuana Program Frequently Asked Questions, https://www.cdph.ca.gov/programs/MMP/Pages/MMPFAQ.aspx#9 (accessed 2 June 2015).

[78]      California Department of Public Health, ' Can a minor apply for a MMIC?', Medical Marijuana Program Frequently Asked Questions, https://www.cdph.ca.gov/programs/MMP/Pages/MMPFAQ.aspx#26 (accessed 2 June 2015).

[79]      California Department of Public Health, 'Where can I get the seeds or plants to start growing marijuana for my medical use? How can I get related products?', Medical Marijuana Program Frequently Asked Questions, https://www.cdph.ca.gov/programs/MMP/Pages/MMPFAQ.aspx#32 (accessed 2 June 2015).

[80]      California Legislative Analyst's Office, Proposal, http://www.lao.ca.gov/ballot/2009/090512.aspx (accessed 2 June 2015).

[81]      Anita Chabria, 'California looks to bring law and order to decades-old medical marijuana market', The Guardian, http://www.theguardian.com/us-news/2015/may/03/california-law-and-order-medical-marijuana-market (accessed 2 June 2015).

[82]      Medical Marijuana Regulation, Second Substitute Senate Bill 5052, Chapter 70 of 2015, s. 2, http://lawfilesext.leg.wa.gov/biennium/2015-16/Pdf/Bills/Session%20Laws/Senate/5052-S2.SL.pdf (accessed 2 June 2015).

[83]      Washington Initiative Measure No. 502, ss. 20(3),  http://sos.wa.gov/_assets/elections/initiatives/i502.pdf (accessed 2 June 2015).

[84]      Washington Initiative Measure No. 502, ss. 15(3), http://sos.wa.gov/_assets/elections/initiatives/i502.pdf (accessed 2 June 2015).

[85]      Washington Initiative Measure No. 502, s. 21, http://sos.wa.gov/_assets/elections/initiatives/i502.pdf (accessed 2 June 2015).

[86]      Medical Marijuana Regulation, Second Substitute Senate Bill 5052, Chapter 70 of 2015, s. 2, http://lawfilesext.leg.wa.gov/biennium/2015-16/Pdf/Bills/Session%20Laws/Senate/5052-S2.SL.pdf (accessed 2 June 2015).

[87]      Congressional Research Service, State Legalization of Recreational Marijuana: Selected Legal Issues, 13 January 2014, p. 3, http://www.fas.org/sgp/crs/misc/R43034.pdf (accessed 2 June 2015).

[88]      Washington State Department of Health, 'What's New' Medical Marijuana (Cannabis), http://www.doh.wa.gov/ForPublicHealthandHealthcareProviders/HealthcareProfessionsandFacilities/MedicalMarijuanaCannabis (accessed 2 June 2015).

[89]      Medical Marijuana Regulation, Second Substitute Senate Bill 5052, Chapter 70 of 2015, s. 2, http://lawfilesext.leg.wa.gov/biennium/2015-16/Pdf/Bills/Session%20Laws/Senate/5052-S2.SL.pdf (accessed 2 June 2015).

[90]      Bureau voor Medicinale Cannabis, 'What is the Office of Medicinal Cannabis?', http://www.cannabisbureau.nl/en/ (accessed 1 June 2015).

[91]      Victorian Law Reform Commission, Medicinal Cannabis: Issues Paper, 17 March 2015, p. 110.

[92]      Victorian Law Reform Commission, Medicinal Cannabis: Issues Paper, 17 March 2015, p. 111.

[93]      Bureau voor Medicinale Cannabis, Medicinal Cannabis: Information for patients, pp 5-7, http://www.cannabisbureau.nl/en/doc/pdf/5089-A5-BMC-Pat-ENG-web_35842.pdf (accessed 1 June 2015).

Chapter 3 - Overview and key provisions of the Bill

[1]        Explanatory Memorandum to the Bill (EM), p. 1.

[2]        EM, p. 1.

[3]        EM, p. 1.

[4]        EM, p. 3.

[5]        Regulator of Medicinal Cannabis Bill 2014, paragraphs 13(2)(b)-(f).

[6]        EM, pp 3-4.

[7]        Regulator of Medicinal Cannabis Bill 2014, paragraphs 16(1)(a)-(e).

[8]        Regulator of Medicinal Cannabis Bill 2014, paragraphs 16(2)(a)-(d).

[9]        Similar offence provisions are contained in clause 21 (in relation to experimental licences) and clause 25 (in relation to import and export licence holders).

[10]      EM, p. 4.

[11]      Regulator of Medicinal Cannabis Bill 2014, paragraphs 20(2)(a)-(f).

[12]      EM, pp 4-5.

[13]      Regulator of Medicinal Cannabis Bill 2014, paragraphs 30(1)(a)-(l).

[14]      EM, p. 6.

[15]      EM, p. 6.

[16]      The Bill notes that Part 3 of the Regulatory Powers Act created a framework for investigating whether offences that are subject to investigation have been committed, and it includes powers of entry, search, inspection and seizure.

[17]      EM, p. 7.

Chapter 4 - Key Issues

[1]        Committee Hansard, 31 March 2015, p. 40.

[2]        Submission 145, pp 1 and 18.

[3]        Committee Hansard, 31 March 2015, p. 17.

[4]        Submission 31, p. 1.

[5]        Mrs Lucy Haslam, Committee Hansard, 31 March 2015, pp 26-27.

[6]        Submission 70, p. 1.

[7]        Submission 52, p. 2.

[8]        Submission 52, pp 5 and 6.

[9]        Committee Hansard, 31 March 2015, p. 9.

[10]      Mr Lance Feeney, National Association of People Living with HIV Australia, Committee Hansard, 31 March 2015, pp 17-18; Ms Carol Ireland, Epilepsy Action Australia, Committee Hansard, 31 March 2015, p. 18.

[11]      Submission 52, p. 8.

[12]      See evidence from the TGA at paragraphs 2.44-2.49.

[13]      Dr Lisa Studdert, TGA, Committee Hansard, 30 March 2015, pp 36-37.

[14]      Committee Hansard, 31 March 2015, p. 11.

[15]      Committee Hansard, 30 March 2015, p. 37.

[16]      Committee Hansard, 31 March 2015, p. 53.

[17]      Committee Hansard, 31 March 2015, p. 5. See also: Professor Wayne Hall, Committee Hansard, 1 April 2015, p. 26.

[18]      Submission 4, p. 6.

[19]      Submission 52, p. 2.

[20]      Dr Alexander Wodak, Australian Drug Law Reform Initiative, Committee Hansard, 31 March 2015, p. 47.

[21]      Professor Iain McGregor, Committee Hansard, 31 March 2015, pp 1-2.

[22]      Committee Hansard, 31 March 2015, pp 2-3.

[23]      Committee Hansard, 31 March 2015, p. 2.

[24]      Committee Hansard, 31 March 2015, pp 5-6.

[25]      See: Mr Paul Benhaim, Committee Hansard, 1 April 2015, pp 30-31; Mr David Gillespie, Submission 47.

[26]      Submission 36, p. 2.

[27]      Committee Hansard, 31 March 2015, p. 50.

[28]      See, for example: Palliative Care Australia, Submission 23, p. 3; Public Health Association of Australia, Submission 26, p. 4; Australian Medical Association, Submission 44, p. 1; ACT Government, Submission 147, p. 2; Emeritus Professor Laurence Mather, Submission 17, p. 8; National Centre for Education and Training on Addiction, Submission 66, p. 1.

[29]      See: Associate Professor Nicholas Lintzeris, Committee Hansard, 31 March 2015, p. 3; Professor Allison Ritter, National Drug and Alcohol Research Centre, Committee Hansard, 31 March 2015, pp 38-39.

[30]      Committee Hansard, 31 March 2015, p. 3.

[31]      Submission 44, p. 1.

[32]      Submission 42, p. 6.

[33]      Submission 18, p. 1.

[34]      Submission 24, p. 2.

[35]      Submission 10, p. 2.

[36]      Committee Hansard, 30 March 2015, p. 34.

[37]      Committee Hansard, 30 March 2015, p. 36.

[38]      Submission 18, p. 1.

[39]      Committee Hansard, 30 March 2015, p. 21.

[40]      Committee Hansard, 30 March 2015, p. 23.

[41]      Committee Hansard, 1 April 2015, p. 24.

[42]      Submission 26, p. 4.

[43]      Submission 52, pp 6-7.

[44]      Dr Alexander Wodak, Australian Drug Law Reform Initiative, Committee Hansard, 31 March 2015, p. 47.

[45]      Dr Alexander Wodak, Australian Drug Law Reform Initiative, Committee Hansard, 31 March 2015, pp 47-48.

[46]      Submission 53, p. 3.

[47]      Submission 18, p. 1.

[48]      Submission 18, p. 2.

[49]      Submission 67, p. 2.

[50]      Committee Hansard, 30 March 2015, pp 34-35.

[51]      Committee Hansard, 30 March 2015, p. 35.

[52]      Submission 67, p. 4.

[53]      Submission 67, pp 4-5.

[54]      Committee Hansard, 30 March 2015, p. 35.

[55]      Submission 67, pp 3–4. 

[56]      Submission 67, p. 4. 

[57]      Submission 67, p. 5.

[58]      Submission 75, p. 1.

[59]      Submission 67, p. 3.

[60]      Submission 67, p. 3.

[61]      Submission 67, p. 3.

[62]      Submission 17, pp 7-8.

[63]      Submission 24, p. 2.

[64]      Submission 66, p. 2.

[65]      Submission 61, p. 2.

[66]      Submission 69, p. 1.

[67]      Submission 69, p. 1.

[68]      Submission 147, p. 2.

[69]      Submission 147, p. 3.

[70]      Committee Hansard, 30 March 2015, pp 35-36.

[71]      Submission 147, p. 3.

[72]      Submission 147, p. 3.

[73]      Submission 147, p. 4.

[74]      Committee Hansard, 31 March 2015, p. 41.

[75]      Submission 37, p. 9.

[76]      Submission 66, p. 1.

[77]      Submission 44, p. 1.

[78]      Submission 37, p. 7.

[79]      Submission 56, [pp 3-4].

[80]      Submission 48, p. 11.

[81]      Submission 23, p. 8.

[82]      Submission 43, [p. 3].

[83]      Submission 37, p. 9.

[84]      Committee Hansard, 1 April 2015, p. 15.

[85]      Submission 66, p. 2.

[86]      Submission 23, p. 8.

[87]      Submission 37, p. 11.

[88]      Submission 9, p. 4.

[89]      Committee Hansard, 1 April 2015, p. 22.

[90]      Submission 4, p. 13.

[91]      Submission 51, p. 1.

[92]      Committee Hansard, 31 March 2015, p. 48.

[93]      Committee Hansard, 31 March 2015, p. 43.

[94]      Submission 44, p. 2. See also: Australian and New Zealand Society for Palliative Medicine, Submission 42, p. 8.

[95]      Submission 51, [p. 5].

[96]      Committee Hansard, 31 March 2015, pp 53-54.

[97]      Submission 42, p. 8.

[98]      Submission 42, p. 9.

[99]      Submission 29, p. 1.

[100]    Submission 66, p. 2.

[101]    Submission 42, p. 8. See also: Bedrocan, Submission 48, p. 12.

[102]    Submission 42, p. 9.

[103]    Submission 23, p. 7.

[104]    Submission 18, p. 2.

[105]    Submission 36, p. 3.

[106]    Submission 36, p. 3; Committee Hansard, 31 March 2015, pp 49-50.

[107]    Submission 31, p. 2.

[108]    Submission 53, p. 1.

[109]    Submission 52, pp 5 and 6.

[110]    Submission 17, p. 8.

[111]    Submission 66, p. 1.

[112]    Submission 37, pp 10-11.

[113]    Submission 37, p. 11.

[114]    Submission 10, p. 2.

[115]    Submission 26, p. 5.

[116]    Submission 23, p. 6.

[117]    Submission 67, p. 5.

[118]    Submission 36, p. 3.

[119]    Committee Hansard, 31 March 2015, p. 50.

[120]    Submission 147, p. 3.

[121]    Committee Hansard, 31 March 2015, p.

[122]    Committee Hansard, 30 March 2015, p. 35.

[123]    Submission 66, p. 2.

[124]    Submission 3, p. 2.

[125]    Submission 43, pp 3 and 6.

[126]    Submission 66, p. 3.

[127]    Submission 30, p. 2.

[128]    Submission 3, p. 2.